Page last updated: 2024-12-07

5-aminoindazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

5-Aminoindazole is a heterocyclic compound that has been investigated for its potential biological activities. It is a derivative of indazole, a bicyclic aromatic compound, and features an amino group at the 5-position. Research into 5-aminoindazole has explored its synthesis, pharmacological effects, and potential therapeutic applications.

Regarding its synthesis, 5-aminoindazole can be prepared through various methods, including the reduction of 5-nitroindazole, the diazotization and subsequent reduction of 5-aminoindazole, or the direct amination of indazole.

Pharmacological studies have revealed that 5-aminoindazole possesses a wide range of biological activities. It has been reported to exhibit anticancer, anti-inflammatory, and antimicrobial properties. Its anticancer activity has been linked to its ability to inhibit the growth of various tumor cell lines, including breast, lung, and colon cancer cells.

Furthermore, 5-aminoindazole has shown potential as a therapeutic agent for inflammatory diseases. It has been demonstrated to suppress the production of pro-inflammatory cytokines, such as TNF-alpha and IL-6, in animal models of inflammation.

The antimicrobial activity of 5-aminoindazole has also been investigated, and it has been shown to exhibit activity against a range of bacterial and fungal pathogens.

The biological activities of 5-aminoindazole have prompted ongoing research efforts to explore its potential as a drug candidate. Researchers are investigating its mechanism of action, exploring its pharmacokinetic properties, and evaluating its therapeutic efficacy in preclinical models.

The study of 5-aminoindazole is driven by its potential to develop novel therapeutic agents for a variety of diseases. The compound's diverse biological activities, including its anticancer, anti-inflammatory, and antimicrobial properties, make it an attractive target for drug development.

Moreover, its relatively simple structure and synthetic accessibility make it a promising starting point for the design and synthesis of novel derivatives with enhanced pharmacological properties.'

Cross-References

ID SourceID
PubMed CID88012
CHEMBL ID17551
SCHEMBL ID117208
MeSH IDM0063904

Synonyms (70)

Synonym
nsc44676
nsc-44676
19335-11-6
5-amino-indazole
AC-1055
MLS001076528
SDCCGMLS-0003169.P003
5-amino-1h-indazole
nsc 44676
1h-indazole, 5-amino-
indazol-5-ylamine
ai3-52443
einecs 242-971-5
5-aminoindazole
1h-indazol-5-amine
5-aminoisoindazole
5-aminoindazole, 97%
MLS000069421 ,
smr000059094
NCGC00018111-01
A0797
CHEMBL17551 ,
bdbm50304148
cid_88012
1h-indazol-5-ylamine
1h-indazol-5-amine;5-amino-1h-indazole
A4258
NCGC00018111-03
NCGC00018111-02
AE-562/40222977
5-indazolamine
1h-indazole-5-amine
BCP9000065
HMS2232B16
unii-a5b06tdt72
a5b06tdt72 ,
AKOS005203106
AM20030258
AB01685
HMS3371D15
FT-0620016
918903-42-1
2h-indazol-5-amine
5-aminobenzopyrazole
AB00384262-15
SCHEMBL117208
mfcd00037975
SY002725
5-aminoindazol
1-h-indazol-5-amine
5aminoindazole
5-aminoazaindole
DTXSID2066480
W-206426
TS-01719
OPERA_ID_1647
8H4 ,
1~{h}-indazol-5-amine
CS-W008621
70S ,
BBL104266
F2108-0020
STL558474
NCGC00018111-04
FT-0762293
5-indazolylamine
BCP00021
SB11754
EN300-18244
HY-33849
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (26)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency10.00000.004023.8416100.0000AID485290
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency3.53970.140911.194039.8107AID2451
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency14.12540.177814.390939.8107AID2147
thioredoxin reductaseRattus norvegicus (Norway rat)Potency79.43280.100020.879379.4328AID588456
ATAD5 protein, partialHomo sapiens (human)Potency16.36010.004110.890331.5287AID504467
USP1 protein, partialHomo sapiens (human)Potency44.66840.031637.5844354.8130AID743255
TDP1 proteinHomo sapiens (human)Potency19.47630.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency12.06270.180013.557439.8107AID1460; AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency35.48130.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency10.00000.00137.762544.6684AID914; AID915
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency14.12540.28189.721235.4813AID2326
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency2.51190.035520.977089.1251AID504332
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency39.50680.036619.637650.1187AID2100
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency28.18380.001815.663839.8107AID894
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency10.00000.794321.275750.1187AID624246
importin subunit beta-1 isoform 1Homo sapiens (human)Potency10.00005.804836.130665.1308AID540263
ras-related protein Rab-9AHomo sapiens (human)Potency5.62340.00022.621531.4954AID485297
snurportin-1Homo sapiens (human)Potency10.00005.804836.130665.1308AID540263
gemininHomo sapiens (human)Potency1.00000.004611.374133.4983AID624297
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency4.46680.00419.962528.1838AID2675
D(3) dopamine receptor isoform eHomo sapiens (human)Potency44.66840.02009.148539.8107AID720506
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Rho-associated protein kinase 2Homo sapiens (human)IC50 (µMol)119.70000.00020.578010.0000AID660234
Nitric oxide synthase, brainHomo sapiens (human)IC50 (µMol)1,000.00000.03502.711910.0000AID449906
Rho-associated protein kinase 1Homo sapiens (human)IC50 (µMol)181.30000.00040.854910.0000AID660233
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
recombinase AMycobacterium tuberculosis H37RvEC50 (µMol)42.35500.018023.2882287.6000AID434968; AID435010
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
replicative DNA helicaseMycobacterium tuberculosis H37RvAC50242.10000.057030.7482325.3000AID449749; AID449750
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (120)

Processvia Protein(s)Taxonomy
epithelial to mesenchymal transitionRho-associated protein kinase 2Homo sapiens (human)
positive regulation of protein phosphorylationRho-associated protein kinase 2Homo sapiens (human)
response to ischemiaRho-associated protein kinase 2Homo sapiens (human)
aortic valve morphogenesisRho-associated protein kinase 2Homo sapiens (human)
protein phosphorylationRho-associated protein kinase 2Homo sapiens (human)
smooth muscle contractionRho-associated protein kinase 2Homo sapiens (human)
canonical NF-kappaB signal transductionRho-associated protein kinase 2Homo sapiens (human)
positive regulation of endothelial cell migrationRho-associated protein kinase 2Homo sapiens (human)
positive regulation of cardiac muscle hypertrophyRho-associated protein kinase 2Homo sapiens (human)
positive regulation of gene expressionRho-associated protein kinase 2Homo sapiens (human)
negative regulation of gene expressionRho-associated protein kinase 2Homo sapiens (human)
positive regulation of centrosome duplicationRho-associated protein kinase 2Homo sapiens (human)
negative regulation of angiogenesisRho-associated protein kinase 2Homo sapiens (human)
actin cytoskeleton organizationRho-associated protein kinase 2Homo sapiens (human)
regulation of cell adhesionRho-associated protein kinase 2Homo sapiens (human)
positive regulation of cell migrationRho-associated protein kinase 2Homo sapiens (human)
cortical actin cytoskeleton organizationRho-associated protein kinase 2Homo sapiens (human)
regulation of nervous system processRho-associated protein kinase 2Homo sapiens (human)
positive regulation of connective tissue growth factor productionRho-associated protein kinase 2Homo sapiens (human)
regulation of actin cytoskeleton organizationRho-associated protein kinase 2Homo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activityRho-associated protein kinase 2Homo sapiens (human)
regulation of circadian rhythmRho-associated protein kinase 2Homo sapiens (human)
positive regulation of MAPK cascadeRho-associated protein kinase 2Homo sapiens (human)
modulation by host of viral processRho-associated protein kinase 2Homo sapiens (human)
negative regulation of nitric oxide biosynthetic processRho-associated protein kinase 2Homo sapiens (human)
regulation of keratinocyte differentiationRho-associated protein kinase 2Homo sapiens (human)
rhythmic processRho-associated protein kinase 2Homo sapiens (human)
centrosome duplicationRho-associated protein kinase 2Homo sapiens (human)
regulation of stress fiber assemblyRho-associated protein kinase 2Homo sapiens (human)
positive regulation of stress fiber assemblyRho-associated protein kinase 2Homo sapiens (human)
regulation of focal adhesion assemblyRho-associated protein kinase 2Homo sapiens (human)
mRNA destabilizationRho-associated protein kinase 2Homo sapiens (human)
negative regulation of biomineral tissue developmentRho-associated protein kinase 2Homo sapiens (human)
cellular response to testosterone stimulusRho-associated protein kinase 2Homo sapiens (human)
response to transforming growth factor betaRho-associated protein kinase 2Homo sapiens (human)
protein localization to plasma membraneRho-associated protein kinase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionRho-associated protein kinase 2Homo sapiens (human)
blood vessel diameter maintenanceRho-associated protein kinase 2Homo sapiens (human)
regulation of angiotensin-activated signaling pathwayRho-associated protein kinase 2Homo sapiens (human)
negative regulation of protein localization to lysosomeRho-associated protein kinase 2Homo sapiens (human)
regulation of cellular response to hypoxiaRho-associated protein kinase 2Homo sapiens (human)
positive regulation of amyloid-beta formationRho-associated protein kinase 2Homo sapiens (human)
positive regulation of protein localization to early endosomeRho-associated protein kinase 2Homo sapiens (human)
positive regulation of amyloid precursor protein catabolic processRho-associated protein kinase 2Homo sapiens (human)
regulation of establishment of endothelial barrierRho-associated protein kinase 2Homo sapiens (human)
negative regulation of bicellular tight junction assemblyRho-associated protein kinase 2Homo sapiens (human)
cellular response to acetylcholineRho-associated protein kinase 2Homo sapiens (human)
positive regulation of connective tissue replacementRho-associated protein kinase 2Homo sapiens (human)
response to angiotensinRho-associated protein kinase 2Homo sapiens (human)
regulation of establishment of cell polarityRho-associated protein kinase 2Homo sapiens (human)
regulation of cell motilityRho-associated protein kinase 2Homo sapiens (human)
actomyosin structure organizationRho-associated protein kinase 2Homo sapiens (human)
peptidyl-threonine phosphorylationRho-associated protein kinase 2Homo sapiens (human)
mitotic cytokinesisRho-associated protein kinase 2Homo sapiens (human)
embryonic morphogenesisRho-associated protein kinase 2Homo sapiens (human)
regulation of cell junction assemblyRho-associated protein kinase 2Homo sapiens (human)
Rho protein signal transductionRho-associated protein kinase 2Homo sapiens (human)
response to hypoxiaNitric oxide synthase, brainHomo sapiens (human)
regulation of sodium ion transportNitric oxide synthase, brainHomo sapiens (human)
arginine catabolic processNitric oxide synthase, brainHomo sapiens (human)
nitric oxide biosynthetic processNitric oxide synthase, brainHomo sapiens (human)
striated muscle contractionNitric oxide synthase, brainHomo sapiens (human)
myoblast fusionNitric oxide synthase, brainHomo sapiens (human)
response to heatNitric oxide synthase, brainHomo sapiens (human)
negative regulation of calcium ion transport into cytosolNitric oxide synthase, brainHomo sapiens (human)
regulation of cardiac muscle contraction by calcium ion signalingNitric oxide synthase, brainHomo sapiens (human)
peptidyl-cysteine S-nitrosylationNitric oxide synthase, brainHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationNitric oxide synthase, brainHomo sapiens (human)
multicellular organismal response to stressNitric oxide synthase, brainHomo sapiens (human)
xenobiotic catabolic processNitric oxide synthase, brainHomo sapiens (human)
vasodilationNitric oxide synthase, brainHomo sapiens (human)
negative regulation of potassium ion transportNitric oxide synthase, brainHomo sapiens (human)
cell redox homeostasisNitric oxide synthase, brainHomo sapiens (human)
positive regulation of DNA-templated transcriptionNitric oxide synthase, brainHomo sapiens (human)
positive regulation of transcription by RNA polymerase IINitric oxide synthase, brainHomo sapiens (human)
negative regulation of hydrolase activityNitric oxide synthase, brainHomo sapiens (human)
negative regulation of serotonin uptakeNitric oxide synthase, brainHomo sapiens (human)
negative regulation of calcium ion transportNitric oxide synthase, brainHomo sapiens (human)
regulation of cardiac muscle contractionNitric oxide synthase, brainHomo sapiens (human)
regulation of ryanodine-sensitive calcium-release channel activityNitric oxide synthase, brainHomo sapiens (human)
cellular response to growth factor stimulusNitric oxide synthase, brainHomo sapiens (human)
positive regulation of the force of heart contractionNitric oxide synthase, brainHomo sapiens (human)
positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwayNitric oxide synthase, brainHomo sapiens (human)
positive regulation of sodium ion transmembrane transportNitric oxide synthase, brainHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelNitric oxide synthase, brainHomo sapiens (human)
positive regulation of membrane repolarization during ventricular cardiac muscle cell action potentialNitric oxide synthase, brainHomo sapiens (human)
positive regulation of guanylate cyclase activityNitric oxide synthase, brainHomo sapiens (human)
nitric oxide mediated signal transductionNitric oxide synthase, brainHomo sapiens (human)
response to hormoneNitric oxide synthase, brainHomo sapiens (human)
negative regulation of blood pressureNitric oxide synthase, brainHomo sapiens (human)
response to lipopolysaccharideNitric oxide synthase, brainHomo sapiens (human)
epithelial to mesenchymal transitionRho-associated protein kinase 1Homo sapiens (human)
aortic valve morphogenesisRho-associated protein kinase 1Homo sapiens (human)
apical constrictionRho-associated protein kinase 1Homo sapiens (human)
protein phosphorylationRho-associated protein kinase 1Homo sapiens (human)
smooth muscle contractionRho-associated protein kinase 1Homo sapiens (human)
leukocyte cell-cell adhesionRho-associated protein kinase 1Homo sapiens (human)
signal transductionRho-associated protein kinase 1Homo sapiens (human)
canonical NF-kappaB signal transductionRho-associated protein kinase 1Homo sapiens (human)
Rho protein signal transductionRho-associated protein kinase 1Homo sapiens (human)
positive regulation of autophagyRho-associated protein kinase 1Homo sapiens (human)
positive regulation of cardiac muscle hypertrophyRho-associated protein kinase 1Homo sapiens (human)
positive regulation of gene expressionRho-associated protein kinase 1Homo sapiens (human)
positive regulation of phosphatase activityRho-associated protein kinase 1Homo sapiens (human)
negative regulation of angiogenesisRho-associated protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationRho-associated protein kinase 1Homo sapiens (human)
membrane to membrane dockingRho-associated protein kinase 1Homo sapiens (human)
actin cytoskeleton organizationRho-associated protein kinase 1Homo sapiens (human)
regulation of cell adhesionRho-associated protein kinase 1Homo sapiens (human)
regulation of cell migrationRho-associated protein kinase 1Homo sapiens (human)
cortical actin cytoskeleton organizationRho-associated protein kinase 1Homo sapiens (human)
neuron projection developmentRho-associated protein kinase 1Homo sapiens (human)
bleb assemblyRho-associated protein kinase 1Homo sapiens (human)
negative regulation of protein bindingRho-associated protein kinase 1Homo sapiens (human)
regulation of actin cytoskeleton organizationRho-associated protein kinase 1Homo sapiens (human)
positive regulation of dephosphorylationRho-associated protein kinase 1Homo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activityRho-associated protein kinase 1Homo sapiens (human)
negative regulation of phosphorylationRho-associated protein kinase 1Homo sapiens (human)
positive regulation of MAPK cascadeRho-associated protein kinase 1Homo sapiens (human)
regulation of keratinocyte differentiationRho-associated protein kinase 1Homo sapiens (human)
regulation of neuron differentiationRho-associated protein kinase 1Homo sapiens (human)
leukocyte migrationRho-associated protein kinase 1Homo sapiens (human)
leukocyte tethering or rollingRho-associated protein kinase 1Homo sapiens (human)
negative regulation of membrane protein ectodomain proteolysisRho-associated protein kinase 1Homo sapiens (human)
myoblast migrationRho-associated protein kinase 1Homo sapiens (human)
regulation of stress fiber assemblyRho-associated protein kinase 1Homo sapiens (human)
regulation of focal adhesion assemblyRho-associated protein kinase 1Homo sapiens (human)
positive regulation of focal adhesion assemblyRho-associated protein kinase 1Homo sapiens (human)
mRNA destabilizationRho-associated protein kinase 1Homo sapiens (human)
negative regulation of biomineral tissue developmentRho-associated protein kinase 1Homo sapiens (human)
regulation of microtubule cytoskeleton organizationRho-associated protein kinase 1Homo sapiens (human)
response to transforming growth factor betaRho-associated protein kinase 1Homo sapiens (human)
protein localization to plasma membraneRho-associated protein kinase 1Homo sapiens (human)
regulation of synapse maturationRho-associated protein kinase 1Homo sapiens (human)
podocyte cell migrationRho-associated protein kinase 1Homo sapiens (human)
motor neuron apoptotic processRho-associated protein kinase 1Homo sapiens (human)
blood vessel diameter maintenanceRho-associated protein kinase 1Homo sapiens (human)
regulation of angiotensin-activated signaling pathwayRho-associated protein kinase 1Homo sapiens (human)
neuron projection arborizationRho-associated protein kinase 1Homo sapiens (human)
positive regulation of amyloid-beta clearanceRho-associated protein kinase 1Homo sapiens (human)
regulation of synaptic vesicle endocytosisRho-associated protein kinase 1Homo sapiens (human)
negative regulation of amyloid-beta formationRho-associated protein kinase 1Homo sapiens (human)
negative regulation of amyloid precursor protein catabolic processRho-associated protein kinase 1Homo sapiens (human)
regulation of establishment of endothelial barrierRho-associated protein kinase 1Homo sapiens (human)
negative regulation of bicellular tight junction assemblyRho-associated protein kinase 1Homo sapiens (human)
positive regulation of connective tissue replacementRho-associated protein kinase 1Homo sapiens (human)
response to angiotensinRho-associated protein kinase 1Homo sapiens (human)
regulation of establishment of cell polarityRho-associated protein kinase 1Homo sapiens (human)
regulation of cell motilityRho-associated protein kinase 1Homo sapiens (human)
negative regulation of motor neuron apoptotic processRho-associated protein kinase 1Homo sapiens (human)
regulation of cell junction assemblyRho-associated protein kinase 1Homo sapiens (human)
mitotic cytokinesisRho-associated protein kinase 1Homo sapiens (human)
embryonic morphogenesisRho-associated protein kinase 1Homo sapiens (human)
peptidyl-threonine phosphorylationRho-associated protein kinase 1Homo sapiens (human)
actomyosin structure organizationRho-associated protein kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (28)

Processvia Protein(s)Taxonomy
protease bindingRho-associated protein kinase 2Homo sapiens (human)
RNA bindingRho-associated protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activityRho-associated protein kinase 2Homo sapiens (human)
structural molecule activityRho-associated protein kinase 2Homo sapiens (human)
protein bindingRho-associated protein kinase 2Homo sapiens (human)
ATP bindingRho-associated protein kinase 2Homo sapiens (human)
small GTPase bindingRho-associated protein kinase 2Homo sapiens (human)
metal ion bindingRho-associated protein kinase 2Homo sapiens (human)
tau protein bindingRho-associated protein kinase 2Homo sapiens (human)
tau-protein kinase activityRho-associated protein kinase 2Homo sapiens (human)
endopeptidase activator activityRho-associated protein kinase 2Homo sapiens (human)
Rho-dependent protein serine/threonine kinase activityRho-associated protein kinase 2Homo sapiens (human)
protein serine kinase activityRho-associated protein kinase 2Homo sapiens (human)
nitric-oxide synthase activityNitric oxide synthase, brainHomo sapiens (human)
calcium channel regulator activityNitric oxide synthase, brainHomo sapiens (human)
protein bindingNitric oxide synthase, brainHomo sapiens (human)
calmodulin bindingNitric oxide synthase, brainHomo sapiens (human)
FMN bindingNitric oxide synthase, brainHomo sapiens (human)
sodium channel regulator activityNitric oxide synthase, brainHomo sapiens (human)
heme bindingNitric oxide synthase, brainHomo sapiens (human)
tetrahydrobiopterin bindingNitric oxide synthase, brainHomo sapiens (human)
arginine bindingNitric oxide synthase, brainHomo sapiens (human)
transmembrane transporter bindingNitric oxide synthase, brainHomo sapiens (human)
cadmium ion bindingNitric oxide synthase, brainHomo sapiens (human)
calcium-dependent protein bindingNitric oxide synthase, brainHomo sapiens (human)
flavin adenine dinucleotide bindingNitric oxide synthase, brainHomo sapiens (human)
NADP bindingNitric oxide synthase, brainHomo sapiens (human)
scaffold protein bindingNitric oxide synthase, brainHomo sapiens (human)
protein kinase activityRho-associated protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityRho-associated protein kinase 1Homo sapiens (human)
protein bindingRho-associated protein kinase 1Homo sapiens (human)
ATP bindingRho-associated protein kinase 1Homo sapiens (human)
small GTPase bindingRho-associated protein kinase 1Homo sapiens (human)
metal ion bindingRho-associated protein kinase 1Homo sapiens (human)
tau protein bindingRho-associated protein kinase 1Homo sapiens (human)
tau-protein kinase activityRho-associated protein kinase 1Homo sapiens (human)
Rho-dependent protein serine/threonine kinase activityRho-associated protein kinase 1Homo sapiens (human)
protein serine kinase activityRho-associated protein kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (28)

Processvia Protein(s)Taxonomy
nucleusRho-associated protein kinase 2Homo sapiens (human)
centrosomeRho-associated protein kinase 2Homo sapiens (human)
cytosolRho-associated protein kinase 2Homo sapiens (human)
plasma membraneRho-associated protein kinase 2Homo sapiens (human)
cytoplasmic ribonucleoprotein granuleRho-associated protein kinase 2Homo sapiens (human)
centrosomeRho-associated protein kinase 2Homo sapiens (human)
cytoskeletonRho-associated protein kinase 2Homo sapiens (human)
cytoplasmRho-associated protein kinase 2Homo sapiens (human)
photoreceptor inner segmentNitric oxide synthase, brainHomo sapiens (human)
nucleoplasmNitric oxide synthase, brainHomo sapiens (human)
cytoplasmNitric oxide synthase, brainHomo sapiens (human)
mitochondrionNitric oxide synthase, brainHomo sapiens (human)
cytosolNitric oxide synthase, brainHomo sapiens (human)
cytoskeletonNitric oxide synthase, brainHomo sapiens (human)
plasma membraneNitric oxide synthase, brainHomo sapiens (human)
sarcoplasmic reticulumNitric oxide synthase, brainHomo sapiens (human)
sarcolemmaNitric oxide synthase, brainHomo sapiens (human)
dendritic spineNitric oxide synthase, brainHomo sapiens (human)
membrane raftNitric oxide synthase, brainHomo sapiens (human)
synapseNitric oxide synthase, brainHomo sapiens (human)
perinuclear region of cytoplasmNitric oxide synthase, brainHomo sapiens (human)
cell peripheryNitric oxide synthase, brainHomo sapiens (human)
protein-containing complexNitric oxide synthase, brainHomo sapiens (human)
plasma membraneNitric oxide synthase, brainHomo sapiens (human)
postsynaptic densityNitric oxide synthase, brainHomo sapiens (human)
cytosolNitric oxide synthase, brainHomo sapiens (human)
nucleusNitric oxide synthase, brainHomo sapiens (human)
Golgi membraneRho-associated protein kinase 1Homo sapiens (human)
ruffleRho-associated protein kinase 1Homo sapiens (human)
extracellular regionRho-associated protein kinase 1Homo sapiens (human)
centrioleRho-associated protein kinase 1Homo sapiens (human)
cytosolRho-associated protein kinase 1Homo sapiens (human)
cytoskeletonRho-associated protein kinase 1Homo sapiens (human)
plasma membraneRho-associated protein kinase 1Homo sapiens (human)
cytoplasmic stress granuleRho-associated protein kinase 1Homo sapiens (human)
lamellipodiumRho-associated protein kinase 1Homo sapiens (human)
blebRho-associated protein kinase 1Homo sapiens (human)
secretory granule lumenRho-associated protein kinase 1Homo sapiens (human)
Schaffer collateral - CA1 synapseRho-associated protein kinase 1Homo sapiens (human)
cytoskeletonRho-associated protein kinase 1Homo sapiens (human)
cytoplasmRho-associated protein kinase 1Homo sapiens (human)
cytoplasmic stress granuleRho-associated protein kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (46)

Assay IDTitleYearJournalArticle
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1728879Prodrug conversion in FAAH-/- mouse brain assessed as N-arachidonoyl conjugate level per g protein at 0.1 mM measured after 20 mins by LC-MS/MS analysis2021European journal of medicinal chemistry, Mar-05, Volume: 213Paracetamol analogues conjugated by FAAH induce TRPV1-mediated antinociception without causing acute liver toxicity.
AID1728912Antipyretic activity against LPS-induced C57BL/6 mouse model of hyperthermia assessed as TXB2 level in diencephalon at 25 mg/kg, ip measured after 40 mins by LC-MS/MS analysis relative to control2021European journal of medicinal chemistry, Mar-05, Volume: 213Paracetamol analogues conjugated by FAAH induce TRPV1-mediated antinociception without causing acute liver toxicity.
AID1728878Substrate activity at FAAH in FAAH+/+ mouse brain assessed as N-arachidonoyl conjugate level per g protein at 0.1 mM measured after 20 mins by LC-MS/MS analysis2021European journal of medicinal chemistry, Mar-05, Volume: 213Paracetamol analogues conjugated by FAAH induce TRPV1-mediated antinociception without causing acute liver toxicity.
AID660233Inhibition of human His-puritin-tagged ROCK1 expressed in Sf9 cells after 1 hr by FRET-based enzyme-coupled assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors.
AID1728895Antinociceptive activity in C57BL/6 mouse assessed as reduction in licking time during first phase at 25 mg/kg, ip treated for 10 mins and measured for 5 mins in presence of TRPV1 antagonist capsazepine by formalin test2021European journal of medicinal chemistry, Mar-05, Volume: 213Paracetamol analogues conjugated by FAAH induce TRPV1-mediated antinociception without causing acute liver toxicity.
AID182522Compound was tested for inhibition of the rat passive cutaneous anaphylaxis (PCA) 1 hr after oral administration; >0<501981Journal of medicinal chemistry, Jan, Volume: 24, Issue:1
Synthesis and study of the potential antiallergic activity of some pyrazole derivatives.
AID182523Compound was tested for inhibition of the rat passive cutaneous anaphylaxis (PCA) 3h after oral administration; >0<501981Journal of medicinal chemistry, Jan, Volume: 24, Issue:1
Synthesis and study of the potential antiallergic activity of some pyrazole derivatives.
AID1728900Antipyretic activity against LPS-induced C57BL/6 mouse model of hyperthermia assessed as reduction in body temperature at 25 mg/kg, ip measured after 48 mins2021European journal of medicinal chemistry, Mar-05, Volume: 213Paracetamol analogues conjugated by FAAH induce TRPV1-mediated antinociception without causing acute liver toxicity.
AID1728886Antinociceptive activity in ip dosed C57BL/6 mouse assessed as reduction in licking time during first phase treated for 10 mins and measured for 5 mins by formalin test2021European journal of medicinal chemistry, Mar-05, Volume: 213Paracetamol analogues conjugated by FAAH induce TRPV1-mediated antinociception without causing acute liver toxicity.
AID1728889Effect on locomotor activity in C57BL/6 mouse assessed as change in latency to fall at 25 mg/kg, ip treated for 10 mins measured up to 60 mins by rotarod test2021European journal of medicinal chemistry, Mar-05, Volume: 213Paracetamol analogues conjugated by FAAH induce TRPV1-mediated antinociception without causing acute liver toxicity.
AID1728884Prodrug conversion in FAAH-/- mouse brain assessed as N-arachidonoyl conjugate level per g protein at 100 mg/kg, ip measured after 20 mins by LC-MS/MS analysis2021European journal of medicinal chemistry, Mar-05, Volume: 213Paracetamol analogues conjugated by FAAH induce TRPV1-mediated antinociception without causing acute liver toxicity.
AID1728882Prodrug conversion in FAAH+/+ mouse brain assessed as N-arachidonoyl conjugate level per g protein at 100 mg/kg, ip measured after 20 mins by LC-MS/MS analysis2021European journal of medicinal chemistry, Mar-05, Volume: 213Paracetamol analogues conjugated by FAAH induce TRPV1-mediated antinociception without causing acute liver toxicity.
AID1728921Hepatotoxicity in C57BL/6 mouse assessed as change in ALT level at 300 mg/kg, ip measured after 12 hrs2021European journal of medicinal chemistry, Mar-05, Volume: 213Paracetamol analogues conjugated by FAAH induce TRPV1-mediated antinociception without causing acute liver toxicity.
AID1728892Antinociceptive activity in C57BL/6 mouse assessed as reduction in licking time during second phase at 25 mg/kg, ip treated for 10 mins and measured for 15 to 40 mins in presence of FAAH inhibitor URB937 by formalin test2021European journal of medicinal chemistry, Mar-05, Volume: 213Paracetamol analogues conjugated by FAAH induce TRPV1-mediated antinociception without causing acute liver toxicity.
AID1728909Antipyretic activity against LPS-induced C57BL/6 mouse model of hyperthermia assessed as PGE2 level in diencephalon at 25 mg/kg, ip measured after 40 mins by LC-MS/MS analysis relative to control2021European journal of medicinal chemistry, Mar-05, Volume: 213Paracetamol analogues conjugated by FAAH induce TRPV1-mediated antinociception without causing acute liver toxicity.
AID1728893Antinociceptive activity in C57BL/6 mouse assessed as reduction in licking time during second phase at 25 mg/kg, ip treated for 10 mins and measured for 15 to 40 mins in presence of TRPV1 antagonist capsazepine by formalin test2021European journal of medicinal chemistry, Mar-05, Volume: 213Paracetamol analogues conjugated by FAAH induce TRPV1-mediated antinociception without causing acute liver toxicity.
AID1728894Antinociceptive activity in C57BL/6 mouse assessed as reduction in licking time during first phase at 25 mg/kg, ip treated for 10 mins and measured for 5 mins in presence of FAAH inhibitor URB937 by formalin test2021European journal of medicinal chemistry, Mar-05, Volume: 213Paracetamol analogues conjugated by FAAH induce TRPV1-mediated antinociception without causing acute liver toxicity.
AID660234Inhibition of ROCK2 after 1 hr by FRET-based enzyme-coupled assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors.
AID1728911Antipyretic activity against LPS-induced C57BL/6 mouse model of hyperthermia assessed as 6-keto-PGF1alpha level in diencephalon at 25 mg/kg, ip measured after 40 mins by LC-MS/MS analysis relative to control2021European journal of medicinal chemistry, Mar-05, Volume: 213Paracetamol analogues conjugated by FAAH induce TRPV1-mediated antinociception without causing acute liver toxicity.
AID1728910Antipyretic activity against LPS-induced C57BL/6 mouse model of hyperthermia assessed as PGF2alpha level in diencephalon at 25 mg/kg, ip measured after 40 mins by LC-MS/MS analysis relative to control2021European journal of medicinal chemistry, Mar-05, Volume: 213Paracetamol analogues conjugated by FAAH induce TRPV1-mediated antinociception without causing acute liver toxicity.
AID1728887Antinociceptive activity in ip dosed C57BL/6 mouse assessed as reduction in licking time during second phase treated for 10 mins and measured for 15 to 40 mins by formalin test2021European journal of medicinal chemistry, Mar-05, Volume: 213Paracetamol analogues conjugated by FAAH induce TRPV1-mediated antinociception without causing acute liver toxicity.
AID1728923Hepatotoxicity in C57BL/6 mouse assessed as centrilobular necrosis at 300 mg/kg, ip measured after 12 hrs by H and E staining based microscopic analysis2021European journal of medicinal chemistry, Mar-05, Volume: 213Paracetamol analogues conjugated by FAAH induce TRPV1-mediated antinociception without causing acute liver toxicity.
AID449906Inhibition of recombinant NOS1 assessed as citrulline formation2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Fluorinated indazoles as novel selective inhibitors of nitric oxide synthase (NOS): synthesis and biological evaluation.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (7.69)18.7374
1990's0 (0.00)18.2507
2000's2 (15.38)29.6817
2010's7 (53.85)24.3611
2020's3 (23.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.05 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]